Comparative Aspects of Canine Melanoma

Nishiya, Adriana Tomoko; Massoco, Cristina de Oliveira; Felizzola, Cláudia Ronca; Perlmann, Eduardo; Batschinski, Karen; Tedardi, Marcello Vannucci; Garcia, Jéssica Soares; Mendonça, Priscila Pedra; Teixeira, Tarso Felipe; Dagli, M.L.

doi:10.3390/vetsci3010007

Cited by 94 publications

(151 citation statements)

References 109 publications

(191 reference statements)

Supporting

Mentioning

131

Contrasting

Unclassified

Order By: Relevance

“…Thoracic x-rays were performed to determine the development of lung metastases or when symptoms appeared. As lymph nodes and lungs are the most common sites of metastatic dissemination[59].…”

Section: Discussionmentioning

confidence: 99%

“…Spontaneous tumors in dogs have many advantages as a human model of disease, they develop in the presence of an intact immune system through the exposure to the same carcinogens[1]. Human and canine malignant melanoma share many histological characteristics such as expression of melanocyte differentiation antigens, melanocyte morphology, patterns of growth necrosis and ulceration.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Predictive factors of response to electrochemotherapy in canine oral malignant melanoma

Tellado

Maglietti

Michinski

et al. 2019

Preprint

View full text Add to dashboard Cite

22Electrochemotherapy is a treatment modality which has been increasingly used in veterinary and 23 human medicine for treating cutaneous and subcutaneous tumors. In this prospective work we 24 evaluated the outcome of using electrochemotherapy as a first-line treatment for canine oral 33 Median overall survival of patients in stage I was 16.5 months, in stage II was 9 months, in stage III 34 7.5 months, and in stage IV 4.5 months. The average number of electrochemotherapy sessions was 35 1.5 for every stage. The incidence of new metastases among treated patients was 28.4%. Patients in 36 advanced stages, with bone involvement, and caudal location of the tumor had poorer response rates 37 and shorter overall survival times. The treatment greatly improved the quality of life of the patients. 38Electrochemotherapy is an important technique in the oncological armamentarium against melanoma, 39 and these results can be used to predict human response to this therapy in each stage. 130Median survival of patients in stage I was 16.5 months (4-30 months, mean 16.27 months), stage II 131 was 9 months (4-21 months, mean 9.95 months), stage III 7.5 months (3-17 months, mean 7.23 132 months) and stage IV 4.5 months (2-7 months, median 4.45 months). 133The average number of ECT sessions was 1.5 for every stage. 157

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Predictive factors of response to electrochemotherapy in canine oral malignant melanoma

Tellado

Maglietti

Michinski

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…Similar classifications have rarely been made for these tumours in exotic species. Ulceration is uncommon and the amount of melanin is variable . Malignancy criteria such as higher mitotic rate, infiltrative growth and cellular pleomorphism warrant the diagnosis of a malignant melanoma.…”

Section: Discussionmentioning

confidence: 99%

“…Ulceration is uncommon and the amount of melanin is variable. 1 Malignancy criteria such as higher mitotic rate, infiltrative growth and cellular pleomorphism warrant the diagnosis of a malignant melanoma. Pigmentary incontinence as a result of tumour cell necrosis is common.…”

Section: Discussionmentioning

confidence: 99%

Diagnosis and treatment of concurrent dermal malignant melanoma and melanocytomas in a pygmy hippopotamus (Choeropsis liberiensis)

Saunders¹,

Killick²,

Barrows³

et al. 2017

Veterinary Dermatology

View full text Add to dashboard Cite

show abstract

“…The recommended treatment for melanoma consists of local tumor control through surgery and/or radiation therapy, as well as systemic treatment, including immunotherapy and oncolytic virotherapy [23]. Vaccination with oncept is also used [24].…”

Section: Introductionmentioning

confidence: 99%

Molecular Mechanisms of Canine Cancers

Cao¹,

Kouznetsova²,

Tsigelny³

2019

obm genet

View full text Add to dashboard Cite

Cancer is the leading cause of death in dogs, and 50 percent of dogs over the age of 10 develop cancer at some point. The most common cancers in dogs include lymphoma, mast cell tumors, osteosarcoma, mammary gland tumors, and melanoma, and many of them share marked similarities with their human counterparts. Although canines are afflicted with many of the same types of cancers as humans, the genetic basis behind these cancers are not as well understood. Thus, the aim of this study is to elucidate some of the molecular mechanisms behind canine cancers. Canine lymphoma mutation patterns generally vary with the type of lymphoma afflicted-B-cell lymphomas have mutations in the alternative NF-kB pathway including MAP3K14, whereas in T-cell lymphomas the mTOR pathway in boxers and cellular metabolism genes in golden retrievers are affected. Mast cell tumors are largely traced to internal tandem duplications and deletions in the juxtamembrane domain of the proto-oncogene c-KIT. In osteosarcoma, mutations in RB1 and TP53 (especially G: C->A:T transitions in exons 4 and 5), as well as CDK4 inhibitors CDKN2A/B are common. Mammary gland tumors are associated with BRCA2 underexpression due to reading frame shift and mutations in BRC repeat 3. Lastly, deletion or underexpression of p16 and PTEN and altered expression of cell-cell adhesion molecules are common factors in the development of melanoma. The genes identified were then studied to identify more key amino acid mutations that changed protein products and promoted tumorigenesis. Genes that altered expression levels of proteins were analyzed separately. Both sets of candidate genes were then analyzed with the Database for Annotation, Visualization, and Integrated Discovery (DAVID) in order to elucidate the molecular pathways involved in canine cancers and identify more genes possibly involved in tumorigenesis. The proposition of this review is that treatments for both canine and human cancers would be enhanced by comparative genomic studies.

show abstract

Comparative Aspects of Canine Melanoma

Cited by 94 publications

References 109 publications

Predictive factors of response to electrochemotherapy in canine oral malignant melanoma

Predictive factors of response to electrochemotherapy in canine oral malignant melanoma

Diagnosis and treatment of concurrent dermal malignant melanoma and melanocytomas in a pygmy hippopotamus (Choeropsis liberiensis)

Molecular Mechanisms of Canine Cancers

Contact Info

Product

Resources

About